Sagent Pharmaceuticals (SGNT) Receiving Somewhat Favorable News Coverage, Report Finds

Press coverage about Sagent Pharmaceuticals (NASDAQ:SGNT) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sagent Pharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.2062802822446 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/27/sagent-pharmaceuticals-sgnt-receiving-somewhat-favorable-news-coverage-report-finds.html.

Sagent Pharmaceuticals Company Profile

Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.

Insider Buying and Selling by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

Receive News & Ratings for Sagent Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply